Soterix begins enrollment for trial of neurostim that treats depression

Parcel-guided rTMS. [Image courtesy of Soterix Medical]Soterix Medical announced today that it began patient recruitment for a trial of its treatment-resistant depression treatment.

The company intends to enroll individuals who received but did not adequately respond to repetitive Transcranial Magnetic Stimulation (rTMS).

Woodbridge, New Jersey-based Soterix, with technology licensed from Columbia University, develops a cloud-based targeting software. The system, based on parcel-guided rTMS, leverages anatomical MRI, machine learning and data. It aims to enable optimized, personalized rTMS therapy.

“Parcel-guided rTMS represents a major technical advance in rTMS therapy by combining three unique [Soterix] technologies,” said Dr. Abishek Datta, CEO and CTO of Soterix. “One, Soterix Medical provides the unique FDA-cleared navigation system, not interrupted by line-of-site issues. Two, Soterix Medical has developed seamless cloud-based system…

Read more
  • 0

Soterix wins IDE for depression treatment trial

Soterix Medical announced today that it received FDA investigational device exemption (IDE) to launch a trial of its tDCS-LTE) neuromodulation system.

New York-based Soterix Medical’s transcranial direct current stimulation-limited total energy (tDCS-LTE) system is an at-home platform for people suffering from major depressive disorder (MDD).

The proprietary technology is designed to support the home-based tDCS, including the single-use SNAPpad electrodes and the ElextraRx digital healthcare platform, according to a news release.

Amid the COVID-19 pandemic, Soterix says there is an even more urgent need for reliable at-home intervention for patients with MDD. With the IDE trial, it’s setting out to benefit those patients whose access to depression therapy has been limited as a result of the pandemic.

“The home-based tDCS-LTE therapy continues our commitment to lead in the creation of innovative non-invasive neuromodulation trea…

Read more
  • 0